trimetrexate has been researched along with Leukemia L5178 in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Leukemia L5178: An experimental lymphocytic leukemia of mice.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balińska, M | 1 |
| Szablewska, I | 1 |
| Janiszewska, D | 1 |
| Bartuzi, K | 1 |
| Pawełczak, K | 1 |
1 other study available for trimetrexate and Leukemia L5178
| Article | Year |
|---|---|
The effects of combined antifolates on inhibition of growth of murine leukemia cells cultured in vitro.
Topics: Animals; Cell Division; Drug Synergism; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Leuke | 1997 |